These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. Ong WL, Koh TL, Lim Joon D, Chao M, Farrugia B, Lau E, Khoo V, Lawrentschuk N, Bolton D, Foroudi F. BJU Int; 2019 Nov 29; 124 Suppl 1():19-30. PubMed ID: 31507035 [Abstract] [Full Text] [Related]
14. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer]. Veliev EI, Tomilov AA, Goncharuk DA, Bogdanov AB, Golubtsova EN. Urologiia; 2018 Jul 29; (3):105-110. PubMed ID: 30035428 [Abstract] [Full Text] [Related]
15. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L. J Nucl Med; 2015 Aug 29; 56(8):1185-90. PubMed ID: 26112024 [Abstract] [Full Text] [Related]
19. 68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy. Henkenberens C, VON Klot CA, Ross TL, Bengel FM, Wester HJ, Katja H, Christiansen H, Derlin T. Anticancer Res; 2017 Mar 29; 37(3):1273-1279. PubMed ID: 28314292 [Abstract] [Full Text] [Related]